清醒经颈注射喉成形术中的抗凝与抗血小板治疗
该回顾性研究纳入2013至2016年因声带运动障碍行清醒经颈注射喉成形术的95例手术,评估继续抗血小板或抗凝治疗是否增加出血并发症。结果显示继续用药与暂停用药者出血并发症无差异,作者认为可维持用药,但需更大样本研究确认。证据等级4。
要点
- 95例清醒经颈注射喉成形术中,44例(46%)使用抗血小板治疗,71例(75%)使用抗凝治疗。
- 抗血小板治疗者均未停药,抗凝治疗者中13例(16.4%)术前暂停用药。
- 继续用药与暂停用药者出血并发症无 observed 差异,但需进一步研究确认。
核心结论
- 作者认为,因声带运动障碍行清醒经颈注射喉成形术的患者可维持抗血小板或抗凝治疗而不增加出血风险,但需更大规模研究确认。
研究设计与样本
- 回顾性研究,纳入2013至2016年在一家三级学术中心因声带运动障碍行清醒注射喉成形术的95例手术。
主要发现
- 95例手术中,44例(46%)为抗血小板治疗患者,71例(75%)为抗凝治疗患者。
- 抗血小板治疗患者均未停药;抗凝治疗患者中13例(16.4%)术前暂停用药。
- 继续抗血小板或抗凝治疗者与暂停用药者之间出血并发症无 observed 差异。
关键数值与推荐
- 抗血小板治疗患者44例(46%),均未停药。
- 抗凝治疗患者71例(75%),其中13例(16.4%)术前暂停用药。
临床怎么用
- 作者认为,因声带运动障碍行清醒经颈注射喉成形术的患者可维持抗血小板或抗凝治疗而不增加出血风险。
- 作者指出需更大规模研究确认上述发现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Vocal fold movement impairment (VFMI) due to neuronal injury occurs in 20% to 30% of surgeries in the region of the aortic arch. Early injection laryngoplasty can aid with postoperative pulmonary toilet in these high-risk cardiovascular patients. The purpose of this study is to determine whether continuing antiplatelet and anticoagulation therapy during awake transcervical injection laryngoplasty surgery is safe, and if there is any increase in bleeding complications in these patients. METHODS: This is a retrospective review of patients undergoing awake injection laryngoplasty surgery for VFMI between 2013 and 2016 at a tertiary academic center specializing in aortic and mediastinal diseases. Records were reviewed for patients regarding baseline antiplatelet or anticoagulation therapy, and whether these medications were stopped or continued preoperatively. The primary outcome was bleeding complications. RESULTS: Of the 95 surgeries reviewed, 44 (46%) were performed for patients on antiplatelet therapy, and 71 (75%) for patients on anticoagulation therapy. None of the patients on antiplatelet therapy had their treatment discontinued. Of the patients on anticoagulation, 13 (16.4%) had their therapy held prior to surgery. There was no observed difference in bleeding complications between patients who were continued on antiplatelet or anticoagulation treatment versus those whose therapy was withheld. CONCLUSION: These results suggest that patients undergoing awake transcervical injection laryngoplasty for VFMI can be maintained on antiplatelet or anticoagulation therapy without increased risk of bleeding. Further larger studies are needed to confirm these findings. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:1850-1854, 2017.
引用
- Dang JH, Liou NE, Ongkasuwan J, et al. Anticoagulation and antiplatelet therapy in awake transcervical injection laryngoplasty. Laryngoscope. 2017. PMID: 28271510. doi:10.1002/lary.26508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。